Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial

BACKGROUND. Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Consolim-Colombo, Fernanda M., Sangaleti, Carine T., Costa, Fernando O., Morais, Tercio L., Lopes, Heno F., Motta, Josiane M., Irigoyen, Maria C., Bortoloto, Luiz A., Rochitte, Carlos Eduardo, Harris, Yael Tobi, Satapathy, Sanjaya K., Olofsson, Peder S., Akerman, Meredith, Chavan, Sangeeta S., MacKay, Meggan, Barnaby, Douglas P., Lesser, Martin L., Roth, Jesse, Tracey, Kevin J., Pavlov, Valentin A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518569/
https://ncbi.nlm.nih.gov/pubmed/28724799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93340
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados